Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 47,425 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the transaction, the insider now directly owns 34,300 shares in the company, valued at approximately $1,181,292. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at 30.73 on Friday. The firm’s market capitalization is $1.55 billion. The company’s 50-day moving average is $25.40 and its 200-day moving average is $25.40. Aimmune Therapeutics, Inc. has a 12-month low of $14.87 and a 12-month high of $37.50.
Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). On average, equities analysts forecast that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/douglas-t-sheehy-sells-47425-shares-of-aimmune-therapeutics-inc-aimt-stock.html.
A number of equities research analysts recently weighed in on AIMT shares. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. Wedbush reaffirmed an “outperform” rating and set a $70.00 price target (up from $42.00) on shares of Aimmune Therapeutics in a report on Monday. Credit Suisse Group raised their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $51.00.
A number of large investors have recently made changes to their positions in AIMT. Nationwide Fund Advisors raised its stake in Aimmune Therapeutics by 23.7% during the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares during the last quarter. Swiss National Bank raised its stake in Aimmune Therapeutics by 17.5% during the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares during the last quarter. American International Group Inc. raised its stake in Aimmune Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares during the last quarter. Teachers Advisors LLC raised its stake in Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock valued at $964,000 after buying an additional 1,120 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Aimmune Therapeutics by 30.5% during the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after buying an additional 513,803 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.